CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
44.25
-0.18 (-0.41%)
At close: Jun 20, 2025, 4:00 PM
44.42
+0.17 (0.38%)
After-hours: Jun 20, 2025, 7:52 PM EDT
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 15 analysts that cover CRISPR Therapeutics AG stock have a consensus rating of "Buy" and an average price target of $70.62, which forecasts a 59.59% increase in the stock price over the next year. The lowest target is $32 and the highest is $120.
Price Target: $70.62 (+59.59%)
Analyst Consensus: Buy
* Price targets were last updated on May 21, 2025.
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 6 | 6 | 6 |
| Buy | 3 | 4 | 4 | 4 | 3 | 2 |
| Hold | 9 | 9 | 9 | 8 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 21 | 21 | 19 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $86 | Buy | Reiterates | $86 | +94.35% | May 21, 2025 |
| Needham | Needham | Strong Buy Reiterates $81 | Strong Buy | Reiterates | $81 | +83.05% | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $65 | Strong Buy | Reiterates | $65 | +46.89% | May 20, 2025 |
| Barclays | Barclays | Hold Maintains $56 → $42 | Hold | Maintains | $56 → $42 | -5.08% | May 9, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $53 → $47 | Hold | Maintains | $53 → $47 | +6.21% | May 8, 2025 |
Financial Forecast
Revenue This Year
48.60M
from 37.31M
Increased by 30.25%
Revenue Next Year
179.15M
from 48.60M
Increased by 268.62%
EPS This Year
-5.52
from -4.34
EPS Next Year
-4.55
from -5.52
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 150.2M | 1.5B | 2.4B | ||
| Avg | 48.6M | 179.2M | 408.9M | ||
| Low | n/a | n/a | 37.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 302.4% | 3,042.0% | 1,213.4% | ||
| Avg | 30.2% | 268.6% | 128.2% | ||
| Low | - | - | -79.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.00 | 2.68 | 4.94 | ||
| Avg | -5.52 | -4.55 | -3.60 | ||
| Low | -6.58 | -6.68 | -7.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.